IP Library Granted Patent US 8,563,302
Granted Patent B2
US 8,563,302 · App. 12/948,061 · Granted Oct 22, 2013

Optimized high yield synthetic plasmids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,302
App. No.
12/948,061
Granted
Oct 22, 2013
Kind
B2
Abstract

One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids) comprising a therapeutic element, and a replication element. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.

Claims (9)

1. A synthetic mammalian expression plasmid comprising:

(a) a synthetic or eukaryotic promoter;

(b) codon-optimized-eukaryotic therapeutic gene sequence;

(c) a poly adenylation signal;

(d) a selectable marker gene sequence operably linked to a selectable marker gene promoter;

(e) a ribosomal binding site; and

(f) an origin of replication comprising a sequence that is SEQ ID No.: 39

wherein elements (a)-(c), above are operatively linked and located in a first operatively-linked arrangement; and elements (d)-(f), above are operatively linked and located in a second operatively-linked arrangement.

2. An isolated nucleic acid having an origin of replication comprising SEQ ID No.:39.

Assignments (4)
MERGER Recorded Feb 2, 2021
From: VGX PHARMACEUTICALS, LLC
To: INOVIO PHARMACEUTICALS, INC.
Reel/Frame 055114/0843 →
MERGER AND CHANGE OF NAME Recorded Dec 21, 2020
From: VGX PHARMACEUTICALS, INC.; INOVIO ACQUISITION, LLC
To: VGX PHARMACEUTICALS, LLC
Reel/Frame 054704/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2013
From: DRAGHIA=AKLI, RUXANDRA; POPE, MELISSA
To: ADVISYS, INC.
Reel/Frame 031124/0609 →
MERGER Recorded Sep 3, 2013
From: ADVISYS INC.
To: VGX PHARMACEUTICALS, INC.
Reel/Frame 031124/0710 →